US Stock MarketDetailed Quotes
ZNTL Zentalis Pharmaceuticals
- 3.375
- +0.195+6.13%
Trading Nov 22 13:05 ET
240.52MMarket Cap-1350P/E (TTM)
3.420High3.080Low589.23KVolume3.200Open3.180Pre Close1.95MTurnover1.06%Turnover RatioLossP/E (Static)71.27MShares18.07052wk High0.68P/B187.67MFloat Cap2.66052wk Low--Dividend TTM55.61MShs Float87.190Historical High--Div YieldTTM10.69%Amplitude2.660Historical Low3.300Avg Price1Lot Size
Zentalis Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -13.91%-44.05M | 55.67%-35.14M | -5.46%-51.97M | -26.91%-207.82M | -8.76%-40.6M | -16.46%-38.67M | -84.24%-79.28M | 1.82%-49.28M | -6.27%-163.75M | -0.83%-37.33M |
| Net income from continuing operations | 27.70%-40.16M | 21.58%-88.28M | 115.87%10.04M | -23.28%-292.31M | -10.83%-60.94M | -1.91%-55.54M | -64.59%-112.56M | -6.79%-63.26M | -42.76%-237.11M | -9.76%-54.98M |
| Operating gains losses | --0 | -99.61%53K | -106.28%-145K | 0.50%16.42M | -94.10%410K | --0 | 153.94%13.7M | 31.92%2.31M | 133.98%16.34M | 279.36%6.95M |
| Depreciation and amortization | -7.76%321K | -4.94%327K | -10.00%324K | -2.59%1.39M | -6.13%337K | -7.20%348K | -1.15%344K | 4.65%360K | 162.13%1.43M | 71.77%359K |
| Deferred tax | --0 | --0 | --0 | -10.92%-853K | --0 | --0 | -1,121.62%-756K | -31.08%-97K | 69.36%-769K | -1,502.08%-769K |
| Other non cash items | --0 | --0 | ---25.56M | --15.05M | --0 | --0 | ---- | ---- | ---- | ---- |
| Change In working capital | -251.87%-7.26M | 373.02%14.1M | -305.70%-16.31M | -55.75%5.86M | 157.80%10.27M | -50.37%4.78M | -277.27%-5.16M | -22.79%-4.02M | -20.19%13.25M | 64.93%3.98M |
| -Change in prepaid assets | 526.00%5.44M | 259.80%1.61M | 63.80%-1.06M | 14.03%-5.68M | 74.64%-479K | -165.59%-1.28M | 59.94%-1.01M | 29.78%-2.92M | -610.43%-6.61M | -369.90%-1.89M |
| -Change in payables and accrued expense | -289.79%-12.01M | 368.48%11.8M | -980.72%-15.25M | -29.68%10.92M | 105.88%10.4M | -1.94%6.33M | -197.10%-4.39M | -182.20%-1.41M | 11.19%15.53M | 205.32%5.05M |
| -Change in other working capital | -154.61%-690K | ---- | ---- | -85.61%623K | -57.42%350K | -122.03%-271K | -73.80%235K | -77.62%309K | 221.46%4.33M | -44.16%822K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -13.91%-44.05M | 55.67%-35.14M | -5.46%-51.97M | -26.91%-207.82M | -8.76%-40.6M | -16.46%-38.67M | -84.24%-79.28M | 1.82%-49.28M | -6.27%-163.75M | -0.83%-37.33M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 141.08%48.24M | -52.71%34.49M | 46.11%61.55M | 61.06%-44.46M | -253.62%-42.06M | -686.73%-117.45M | 151.32%72.93M | 112.78%42.12M | -530.31%-114.18M | -127.49%-11.89M |
| Net PPE purchase and sale | --0 | 63.64%-116K | ---40K | 77.12%-583K | -8.13%-173K | 94.52%-91K | -14.75%-319K | --0 | 58.28%-2.55M | 92.70%-160K |
| Net business purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- |
| Net investment purchase and sale | 141.11%48.24M | -52.76%34.61M | 46.21%61.59M | 60.70%-43.88M | -256.97%-41.89M | -641.38%-117.36M | 151.65%73.25M | 108.05%42.12M | -4,928.37%-111.63M | -125.81%-11.73M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 141.08%48.24M | -52.71%34.49M | 46.11%61.55M | 61.06%-44.46M | -253.62%-42.06M | -686.73%-117.45M | 151.32%72.93M | 112.78%42.12M | -530.31%-114.18M | -127.49%-11.89M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -70.23%92K | -100.00%9K | -98.12%7K | -9.09%237.3M | 0 | -47.54%309K | 12.97%236.62M | -70.35%373K | 46.23%261.04M | 305.49%49.74M |
| Net common stock issuance | -70.23%92K | -100.00%9K | -33.51%248K | -9.09%237.3M | --0 | -47.54%309K | 12.97%236.62M | -70.35%373K | 45.29%261.04M | 270.84%49.74M |
| Net other financing activities | --0 | --0 | ---241K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -70.23%92K | -100.00%9K | -98.12%7K | -9.09%237.3M | --0 | -47.54%309K | 12.97%236.62M | -70.35%373K | 46.23%261.04M | 305.49%49.74M |
| Net cash flow | ||||||||||
| Beginning cash position | -85.27%39.66M | 3.57%40.3M | -32.78%30.72M | -26.98%45.7M | 150.96%113.38M | 365.96%269.19M | 16.34%38.91M | -26.98%45.7M | 11.22%62.58M | 2.51%45.18M |
| Current changes in cash | 102.75%4.29M | -100.28%-640K | 241.08%9.58M | 11.32%-14.98M | -16,057.34%-82.66M | -1,137.35%-155.81M | 846.56%230.28M | 76.70%-6.79M | -367.51%-16.89M | -97.20%518K |
| End cash Position | -61.24%43.95M | -85.27%39.66M | 3.57%40.3M | -32.78%30.72M | -32.78%30.72M | 150.96%113.38M | 365.96%269.19M | 16.34%38.91M | -26.98%45.7M | -26.98%45.7M |
| Free cash flow | -13.65%-44.05M | 55.62%-35.32M | -5.54%-52.01M | -25.32%-208.41M | -8.76%-40.77M | -11.18%-38.76M | -83.80%-79.59M | 2.69%-49.28M | -3.81%-166.3M | 4.39%-37.49M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data